Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 120 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR High Frequency of Germline ATM Variants in CLL November 11, 2022 FDA Approves Talazoparib with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate... July 6, 2023 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Addition of an EGFR Antibody to Fluorouracil/Folinic Acid Maintenance Therapy in... September 22, 2021 Load more HOT NEWS Zolbetuximab plus CAPOX Prolongs Survival in CLDN18.2-positive, HER2-negative, Locally Advanced Unresectable... Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... 3…2…1…Countdown to Medicare Open Enrollment Survival Benefit of Enfortumab Vedotin and Pembrolizumab Compared with Chemotherapy in...
